Nootropil: Enhance Cognitive Function with Piracetam
| Product dosage: 800mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $1.11 | $66.34 (0%) | 🛒 Add to cart |
| 90 | $1.07 | $99.50 $96.49 (3%) | 🛒 Add to cart |
| 120 | $1.05 | $132.67 $125.64 (5%) | 🛒 Add to cart |
| 180 | $1.03 | $199.01 $184.94 (7%) | 🛒 Add to cart |
| 270 | $1.02 | $298.51 $274.39 (8%) | 🛒 Add to cart |
| 360 | $1.01
Best per pill | $398.01 $364.85 (8%) | 🛒 Add to cart |
Synonyms
| |||
Nootropil, the pioneering nootropic medication containing the active substance Piracetam, represents a significant advancement in cognitive pharmacotherapy. As a cyclic derivative of the neurotransmitter GABA, it exhibits unique neuroprotective and neuroenhancement properties without functioning as a sedative or stimulant. Clinically, it is indicated for cortical myoclonus and utilized off-label for cognitive enhancement, demonstrating a favorable safety profile that has been established through decades of clinical use and research. This comprehensive product card provides expert medical information for healthcare professionals considering this cognitive enhancer.
Features
- Active ingredient: Piracetam 800mg or 1200mg per tablet
- Pharmaceutical form: Film-coated tablets
- Mechanism: Modulates neurotransmitter systems, particularly enhancing cholinergic and glutamatergic transmission
- Pharmacokinetics: Rapidly absorbed with peak plasma concentrations within 1 hour
- Bioavailability: Nearly 100% with minimal protein binding
- Elimination: Renal excretion with half-life of 4-5 hours
- Manufacturing: Produced under GMP conditions with consistent purity standards
Benefits
- Enhances learning capacity and memory consolidation through improved neuronal plasticity
- Supports cognitive recovery following cerebral ischemia or traumatic brain injury
- Reduces the severity and frequency of cortical myoclonic jerks
- Improves interhemispheric transfer of information through corpus callosum
- Provides neuroprotective effects against hypoxic and toxic damage
- Facilitates rehabilitation in cognitive disorders without significant sedation
Common use
Nootropil is primarily prescribed for the treatment of cortical myoclonus, either as monotherapy or as adjunctive treatment. Beyond its approved indication, it is extensively used off-label for cognitive enhancement in age-related memory decline, dyslexia, and cognitive sequelae of cerebrovascular accidents. The medication has shown particular efficacy in situations requiring enhanced mental performance and accelerated recovery from neuronal injury. Clinical applications extend to supporting cognitive function in mild cognitive impairment and as adjunctive therapy in vertigo of central origin.
Dosage and direction
For cortical myoclonus: Initial dose of 7.2g daily divided into 2-3 doses, increasing by 4.8g daily every 3-4 days to maximum of 24g daily. Maintenance dose is typically 12-24g daily divided into 2-3 doses.
For cognitive enhancement: 1.2-4.8g daily divided into 2-3 doses, typically starting at lower range and titrating based on response.
Administration: Tablets should be swallowed whole with water, preferably with meals to minimize potential gastrointestinal discomfort. Dosage adjustment is necessary in renal impairment. Treatment duration varies by indication but often requires several weeks to manifest full therapeutic effects.
Precautions
Renal function should be assessed before initiation and monitored periodically during treatment, particularly in elderly patients. Dose reduction is mandatory in renal impairment (creatinine clearance <60 mL/min). Use with caution in patients with history of hemorrhagic diathesis or those undergoing surgical procedures due to potential effects on platelet aggregation. Patients should be monitored for behavioral changes, particularly those with history of anxiety or agitation. Abrupt discontinuation should be avoided, particularly in epilepsy patients, due to potential rebound effects.
Contraindications
Hypersensitivity to piracetam or any excipients in the formulation. Severe renal impairment (creatinine clearance <20 mL/min). Patients with cerebral hemorrhage. Huntington’s chorea due to potential exacerbation of symptoms. Pregnancy and lactation unless absolutely necessary and under strict medical supervision.
Possible side effects
Most common: Nervousness (5-10%), weight gain (3-5%), somnolence (2-4%), depression (1-3%) Less common: Gastrointestinal discomfort, diarrhea, insomnia, headache, dizziness, anxiety, agitation Rare: Hyperkinesia, rash, pruritus, angioedema, decreased blood pressure Very rare: Thrombophlebitis, coagulation disorders, seizures in patients with pre-existing epilepsy
Drug interaction
Anticoagulants/Antiplatelets: May enhance effects of warfarin, aspirin, and other anticoagulants requiring increased monitoring of coagulation parameters. Psychoactive medications: May potentiate effects of antidepressants, antipsychotics, and anxiolytics. Thyroid hormones: Potential interaction requiring monitoring of thyroid function. Antiepileptics: Altered seizure threshold may require adjustment of antiepileptic medication.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for the missed administration. Maintain regular dosing schedule to ensure stable plasma concentrations. Patients should be advised to maintain a consistent dosing routine to optimize therapeutic effects.
Overdose
Symptoms: Increased severity of adverse effects, particularly gastrointestinal distress and neurological symptoms including insomnia and agitation. Management: Gastric lavage may be considered if ingestion occurred within previous 2 hours. Symptomatic and supportive treatment is recommended. Hemodialysis may be effective due to low protein binding and renal excretion. No specific antidote exists. Medical supervision is advised for ingestions exceeding 3 times the daily therapeutic dose.
Storage
Store at room temperature (15-30°C) in original packaging protected from moisture and light. Keep out of reach of children. Do not use after expiration date printed on packaging. Tablets should be protected from crushing or breaking. Do not transfer to alternative containers as this may affect stability.
Disclaimer
This information is intended for healthcare professionals and should not replace professional medical advice. Dosage and administration should be determined by a qualified physician based on individual patient needs. Off-label use should be carefully considered against available evidence and patient-specific factors. Patients should be fully informed about potential benefits and risks before initiation of therapy.
Reviews
Clinical studies demonstrate significant improvement in cortical myoclonus in 60-70% of patients, with complete resolution in approximately 30% of cases. Cognitive studies show modest but statistically significant improvements in memory recall and learning capacity across various populations. Long-term safety data from observational studies indicate favorable tolerability profile with most adverse effects being mild and transient. Patient-reported outcomes generally reflect improvements in quality of life measures related to cognitive function and reduction in myoclonic symptoms.